Floatz logo

Adagrasib

KRAS G12C

Ryan Gentzler, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Opnurasib
Maastricht University Medical Center
Phase 2CCC
Fulzerasib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2CCC
Glecirasib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2CC

View all 23 →

Same molecule, other indications

Adagrasib is also rated in:

lung cancerDormant
BB
Indicative ·
64 / 100
View asset →
metastatic malignant neoplasmDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →